Federal officials on Friday reversed Trump administration restrictions on using human fetal tissue for medical research.
The changes clear the way for using government money on work that in the past has led to treatments for a variety of diseases, including COVID-19.
Government scientists now will be able to resume research that uses tissue from elective abortions. Scientists at universities also can now apply for federal grants without getting approval from a special ethics panel for any such work.
Health and Human Services Secretary Xavier Becerra determined there were “no new ethical issues that require special review,” so the agency will return to using procedures that had been in place for decades before the Trump policy change in June 2019, a statement from the agency said.
Those include following applicable laws, such as obtaining informed consent from anyone donating such tissue. The changes were detailed in a notice to researchers.
Two dozen members of Congress who had written to Becerra urging the change praised the move. The restrictions were “politically motivated and unnecessary,” they wrote earlier this week.
The American Society of Reproductive Medicine also issued a statement applauding the change. “The United States government has developed a robust system of oversight. …. Ideologically driven politicians must not be allowed to interfere with this system on a whim,” the group said.
Research using fetal tissue led to vaccines for rubella and rabies and drugs to treat HIV. But such work has long been targeted by anti-abortion opponents.
Coronavirus: US states urge end to ban on fetal research
© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
Federal officials reverse limits on fetal tissue research (2021, April 16)
retrieved 16 April 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022